BNTX News
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
MRNA's respiratory vaccine expansion and promising oncology results offer potential growth as COVID-19 demand normalizes.
Zacks
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
Moderna (NASDAQ: MRNA) has delivered the pivotal cancer result investors were waiting for, while BioNTech Se (NASDAQ: BNTX) offers greater financial flexibility and a broader oncology pipeline. The question is whether Moderna's stronger clinical proof deserves its valuation premi...
Nasdaq News: Markets
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers New York, NY – September 15, 2026 – Market News Updates News Commentary – The antiviral market is entering a period where the need for new treatments is becoming impossible […]
The post A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat appeared first on Financial News Media.
Financial News Media
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Zacks
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.
Zacks
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
Zacks
BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’
BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients.
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY XFG...
Business Wire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology New York, NY – August 26, 2026 – Market News Updates News Commentary – If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of […]
The post A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity appeared first on Financial News Media.
Financial News Media